跳至主要内容
临床试验/NCT04879693
NCT04879693Unknown不适用

Effectiveness and Safety of the Dexcom G6 Continuous Glucose Monitoring System in Non-Critically Ill Patients in the Inpatient Setting

DexCom, Inc.0 个研究点目标入组 250 人开始时间: 2021年6月最近更新:
适应症

试验速览

阶段
不适用
发起方
DexCom, Inc.
入组人数
250
主要终点
System Performance

研究概览

简要总结

Effectiveness and Safety of the Dexcom G6 Continuous Glucose Monitoring System in Non-Critically Ill Patients in the Inpatient Setting

详细描述

To assess the performance of the CGM System in comparison to a blood glucose comparator method in non-critically ill hospitalized patients who need glucose control.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Other
盲法
None

盲法说明

All systems worn will be blinded. All sensor insertions will be performed at the clinic by subjects and/or caregivers.

入排标准

年龄范围
18 Years 至 120 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 18 years of age and older
  • Admitted to the hospital in a non-ICU bed or once transferred out of ICU
  • Anticipate at least 48 hours of hospital stay
  • On treatment for glucose control.
  • Willingness to complete the study.
  • Willingness to wear up to 3 CGM systems simultaneously. Two in the abdomen and one on the back of the arm or one on each arm and one on the abdomen.
  • Subject and/or caretaker are able to speak, read, and write English

排除标准

  • Presence of extensive skin changes/diseases at sensor wear site(s) that preclude wearing the sensor(s) on normal skin (e.g., extensive psoriasis, recent burns or severe sunburn, extensive eczema, extensive scarring, extensive tattoos, dermatitis herpetiformis)
  • Currently in an intensive care unit (ICU) of the following type (does not apply to participants placed in an ICU bed due to space issues in the non-ICU areas)
  • Known allergy to medical-grade adhesives
  • Pregnancy, demonstrated by a positive test (for subjects of childbearing potential)
  • Women admitted to give birth or any other admission related to pregnancy
  • Patients receiving Hydroxyurea
  • Bleeding disorder
  • Participants that are currently being treated for malignancies, cancer
  • Participant that are hospitalized to receive an organ transplant
  • Require a Magnetic Resonance Imaging (MRI) scan
  • End stage renal disease and currently managed by dialysis or anticipating initiating dialysis during the study wear period
  • Current participation in another investigational study protocol (If a subject has recently completed participation in another drug study, the subject must have completed that study at least 7 days prior to being enrolled in this study.)
  • Any condition that, in the opinion of the Investigator, would interfere with their participation in the trial or pose an excessive risk to study staff (e.g., known history of hepatitis B or C)

结局指标

主要结局

System Performance

时间窗: Up to 10 days

Assess the performance of the CGM System in comparison to a blood glucose comparator method in non-critically ill hospitalized patients who need glucose control.

次要结局

未报告次要终点

研究者

发起方
DexCom, Inc.
申办方类型
Industry
责任方
Sponsor

相似试验